BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26899588)

  • 1. Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression--The EMC trial.
    Tadić A; Wachtlin D; Berger M; Braus DF; van Calker D; Dahmen N; Dreimüller N; Engel A; Gorbulev S; Helmreich I; Kaiser AK; Kronfeld K; Schlicht KF; Tüscher O; Wagner S; Hiemke C; Lieb K
    Eur Neuropsychopharmacol; 2016 Apr; 26(4):705-16. PubMed ID: 26899588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder.
    Dreimüller N; Wagner S; Engel A; Braus DF; Roll SC; Elsner S; Tadić A; Lieb K
    BMC Psychiatry; 2019 Jan; 19(1):24. PubMed ID: 30642308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder--the EMC trial.
    Tadić A; Gorbulev S; Dahmen N; Hiemke C; Braus DF; Röschke J; van Calker D; Wachtlin D; Kronfeld K; Gorbauch T; Seibert-Grafe M; Lieb K;
    Trials; 2010 Feb; 11():21. PubMed ID: 20187947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of nonremission to antidepressant therapy using diffusion tensor imaging.
    Grieve SM; Korgaonkar MS; Gordon E; Williams LM; Rush AJ
    J Clin Psychiatry; 2016 Apr; 77(4):e436-43. PubMed ID: 27137427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
    Bobo WV; Chen H; Trivedi MH; Stewart JW; Nierenberg AA; Fava M; Kurian BT; Warden D; Morris DW; Luther JF; Husain MM; Cook IA; Lesser IM; Kornstein SG; Wisniewski SR; Rush AJ; Shelton RC
    J Affect Disord; 2011 Oct; 133(3):467-76. PubMed ID: 21601287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram.
    Souery D; Calati R; Papageorgiou K; Juven-Wetzler A; Gailledreau J; Modavi D; Sentissi O; Pitchot W; Papadimitriou GN; Dikeos D; Montgomery S; Kasper S; Zohar J; Serretti A; Mendlewicz J
    World J Biol Psychiatry; 2015 Oct; 16(7):472-82. PubMed ID: 25535987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
    Sung SC; Wisniewski SR; Balasubramani GK; Zisook S; Kurian B; Warden D; Trivedi MH; Rush AJ;
    Psychol Med; 2013 May; 43(5):945-60. PubMed ID: 23228340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial.
    Williams LM; Korgaonkar MS; Song YC; Paton R; Eagles S; Goldstein-Piekarski A; Grieve SM; Harris AW; Usherwood T; Etkin A
    Neuropsychopharmacology; 2015 Sep; 40(10):2398-408. PubMed ID: 25824424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early switch strategy in patients with major depressive disorder: a double-blind, randomized study.
    Romera I; Pérez V; Menchón JM; Schacht A; Papen R; Neuhauser D; Abbar M; Svanborg P; Gilaberte I
    J Clin Psychopharmacol; 2012 Aug; 32(4):479-86. PubMed ID: 22722513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.
    McGrath PJ; Stewart JW; Fava M; Trivedi MH; Wisniewski SR; Nierenberg AA; Thase ME; Davis L; Biggs MM; Shores-Wilson K; Luther JF; Niederehe G; Warden D; Rush AJ
    Am J Psychiatry; 2006 Sep; 163(9):1531-41; quiz 1666. PubMed ID: 16946177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of event-related potentials in predicting antidepressant treatment response: An iSPOT-D report.
    van Dinteren R; Arns M; Kenemans L; Jongsma ML; Kessels RP; Fitzgerald P; Fallahpour K; Debattista C; Gordon E; Williams LM
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):1981-90. PubMed ID: 26282359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A; Korotzer A; Gommoll C; Li D
    Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
    Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
    J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting Remission in Late-Life Major Depression: A Clinical Algorithm Based Upon Past Treatment History.
    Buchalter ELF; Oughli HA; Lenze EJ; Dixon D; Miller JP; Blumberger DM; Karp JF; Reynolds CF; Mulsant BH
    J Clin Psychiatry; 2019 Dec; 80(6):. PubMed ID: 31846575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
    Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
    Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
    Gaynes BN; Dusetzina SB; Ellis AR; Hansen RA; Farley JF; Miller WC; Stürmer T
    J Clin Psychopharmacol; 2012 Feb; 32(1):114-9. PubMed ID: 22198447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder.
    Montgomery SA; Huusom AK; Bothmer J
    Neuropsychobiology; 2004; 50(1):57-64. PubMed ID: 15179022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.